{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:31Z","timestamp":1788516451323,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006070","name":"Universidad de los Andes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.02.085","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:27:58Z","timestamp":1709800078000},"page":"2414-2420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia"],"prefix":"10.1016","volume":"42","author":[{"given":"Ivette","family":"Maldonado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rodr\u00edguez Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos F.","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"D'silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Castro Villarreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.02.085_b0005","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva, Switzerland: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO."},{"issue":"2","key":"10.1016\/j.vaccine.2024.02.085_b0010","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health [Internet]"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.085_b0015","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/cncr.27894","article-title":"Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010","volume":"119","author":"Laz","year":"2013","journal-title":"Cancer [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.085_b0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/21645515.2018.1511667","article-title":"HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia","volume":"15","author":"Simas","year":"2019","journal-title":"Hum Vaccin Immunother [Internet]"},{"key":"10.1016\/j.vaccine.2024.02.085_b0025","unstructured":"Ministry of Health and Social Protection. Observatorio nacional de c\u00e1ncer. L\u00ednea Estrat\u00e9gica 1. Componente vacunaci\u00f3n [Internet]. [Accessed June 10, 2023]. Available from: https:\/\/www.sispro.gov.co\/observatorios\/oncancer\/Paginas\/cobertura-vacunacion.aspx."},{"issue":"4","key":"10.1016\/j.vaccine.2024.02.085_b0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.adaj.2019.10.010","article-title":"Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines","volume":"151","author":"Villa","year":"2020","journal-title":"J Am Dent Assoc [Internet]"},{"key":"10.1016\/j.vaccine.2024.02.085_b0035","unstructured":"Ministry of Health and Social Protection. Health Benefits Information System [Internet]. [Accessed June 10, 2023]. Available from: https:\/\/www.minsalud.gov.co\/proteccionsocial\/Paginas\/rips.aspx."},{"key":"10.1016\/j.vaccine.2024.02.085_b0040","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstrom","year":"2013","journal-title":"BMJ [Internet]."},{"issue":"4","key":"10.1016\/j.vaccine.2024.02.085_b0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med [Internet]"},{"issue":"2","key":"10.1016\/j.vaccine.2024.02.085_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.085_b0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA [Internet]."},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.085_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14760584.2018.1388168","article-title":"Absence of association between guillain-barr\u00e9 syndrome hospitalizations and HPV-vaccine","volume":"17","author":"Deceuninck","year":"2018","journal-title":"Expert Rev Vaccines [Internet]"},{"issue":"33","key":"10.1016\/j.vaccine.2024.02.085_b0065","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2017.06.031","article-title":"HPV vaccination and risk of chronic fatigue syndrome\/myalgic encephalomyelitis: a nationwide register-based study from Norway","volume":"35","author":"Feiring","year":"2017","journal-title":"Vaccine [Internet]"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.085_b0070","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human Papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA [Internet]."},{"issue":"21","key":"10.1016\/j.vaccine.2024.02.085_b0075","article-title":"Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario grade 8 HPV vaccine cohort study","volume":"190","author":"Liu","year":"2018","journal-title":"CMAJ [Internet]"},{"key":"10.1016\/j.vaccine.2024.02.085_b0080","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun [Internet]"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:30:58Z","timestamp":1723059058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24002639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24002639"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}